{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:40:09Z","timestamp":1793752809071,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Prostate cancer (PCa) is the most frequently diagnosed malignancy among men in Germany. Advances in diagnostics and treatment have transformed PCa into a\u00a0chronic disease. Given the heterogeneity of PCa, there is a\u00a0need for additional stratification tools. This review focuses on updating the evidence for genomic classifiers (GC; Decipher [Veracyte Inc.\u00a0San Diego, CA, USA], Prolaris [Myriad Genetics, Inc., Salt Lake City, UT], and Oncotype DX [Exact Sciences, Madison, WI, USA] tests) and artificial intelligence (AI)-based digital histopathology biomarkers (ArteraAI Prostate Test) in the context of radiotherapy (RT) for PCa.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The members of the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO) conducted an updated literature search on GCs and histopathological biomarkers in PCa, covering original articles published between January 2022 and February 2024 in the PubMed database.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In addition to previous reviews, 11\u00a0relevant studies were identified, of which nine studies analyzed biomarkers within prospective phase\u00a0II or III trials. Eight trials focused on genomic biomarkers, of which three addressed GCs in primary localized PCa, three in recurrent PCa in the setting of salvage RT, and two in metastatic castration-sensitive PCa. In localized PCa, GCs could be validated in a\u00a0retrospective analysis of randomized controlled trials. Additionally, three studies reported on AI-based histopathology biomarkers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Genomic classifiers and AI-based digital histopathology models might have superior prognostic and predictive value compared to established clinical and pathological parameters in localized, recurrent, and metastatic PCa. Despite promising results, prospective validation of these biomarkers in randomized trials remains limited. This review underscores the need for further prospective trials to confirm the usefulness of these biomarkers in PCa.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00066-025-02388-x","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T09:19:10Z","timestamp":1743153550000},"page":"759-766","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biomarkers in prostate cancer: current status and future directions in radiotherapy\u2014statement from the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO)"],"prefix":"10.1007","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2727-8005","authenticated-orcid":false,"given":"S. K.B.","family":"Spohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Aebersold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Boehmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Ganswindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.-S.","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hoecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Koerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-C.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Niehoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Peeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pinkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"2388_CR1","doi-asserted-by":"crossref","unstructured":"Zamboglou\u00a0C, Spohn\u00a0SKB, Adebahr\u00a0S, Huber\u00a0M, Kirste\u00a0S, Sprave\u00a0T et\u00a0al. (2021) PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (hypofocal-SBRT): study protocol of a randomized, multicentric phase III trial. Cancers (Basel) 13(22):5795","DOI":"10.3390\/cancers13225795"},{"issue":"5","key":"2388_CR2","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","volume":"113","author":"C Zamboglou","year":"2022","unstructured":"Zamboglou\u00a0C, Spohn\u00a0SKB, Ruf\u00a0J, Benndorf\u00a0M, Gainey\u00a0M, Kamps\u00a0M et\u00a0al (2022) PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: planned safety analysis of a\u00a0nonrandomized 2\u2011armed phase\u00a02 trial (ARO2020-01). Int J Radiat Oncol Biol Phys 113(5):1025\u20131035","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2388_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer\u00a0LGW, Groen\u00a0VH, Pos\u00a0FJ, Haustermans\u00a0K, Monninkhof\u00a0EM, Smeenk\u00a0RJ et\u00a0al (2021) Focal boost to the Intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase\u00a0III trial. JCO 39(7):787\u2013796","journal-title":"JCO"},{"issue":"5","key":"2388_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/MOU.0000000000000419","volume":"27","author":"S Loeb","year":"2017","unstructured":"Loeb\u00a0S, Ross\u00a0AE (2017) Genomic testing for localized prostate cancer: where do we go from here? Curr Opin Urol 27(5):495\u2013499","journal-title":"Curr Opin Urol"},{"issue":"4","key":"2388_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.4103\/1008-682X.175096","volume":"18","author":"R Na","year":"2016","unstructured":"Na\u00a0R, Wu\u00a0Y, Ding\u00a0Q, Xu\u00a0J (2016) Clinically available RNA profiling tests of prostate tumors: utility and comparison. Asian J Androl 18(4):575\u2013579","journal-title":"Asian J Androl"},{"issue":"3","key":"2388_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ijrobp.2022.12.038","volume":"116","author":"SKB Spohn","year":"2023","unstructured":"Spohn\u00a0SKB, Draulans\u00a0C, Kishan\u00a0AU, Spratt\u00a0D, Ross\u00a0A, Maurer\u00a0T et\u00a0al (2023) Genomic classifiers in personalized prostate cancer radiation therapy approaches: a\u00a0systematic review and future perspectives based on international consensus. Int J Radiat Oncol Biol Phys 116(3):503\u2013520","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2388_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41746-022-00613-w","volume":"5","author":"A Esteva","year":"2022","unstructured":"Esteva\u00a0A, Feng\u00a0J, van der Wal\u00a0D, Huang\u00a0S\u2011C, Simko\u00a0JP, DeVries\u00a0S et\u00a0al (2022) Prostate cancer therapy personalization via multi-modal deep learning on randomized phase\u00a0III clinical trials. Npj Digit Med 5(1):71","journal-title":"Npj Digit Med"},{"issue":"9","key":"2388_CR8","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.annonc.2022.05.007","volume":"33","author":"A Dal Pra","year":"2022","unstructured":"Dal Pra\u00a0A, Ghadjar\u00a0P, Hayoz\u00a0S, Liu\u00a0VYT, Spratt\u00a0DE, Thompson\u00a0DJS et\u00a0al (2022) Validation of the decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy\u2014an ancillary study of the SAKK 09\/10 randomized clinical trial. Ann Oncol 33(9):950\u2013958","journal-title":"Ann Oncol"},{"issue":"3","key":"2388_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","volume":"116","author":"PL Nguyen","year":"2023","unstructured":"Nguyen\u00a0PL, Huang\u00a0HR, Spratt\u00a0DE, Davicioni\u00a0E, Sandler\u00a0HM, Shipley\u00a0WU et\u00a0al (2023) Analysis of a\u00a0biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the NRG oncology\/radiation therapy oncology group 9202, 9413, and 9902 phase\u00a03 randomized trials. Int J Radiat Oncol Biol Phys 116(3):521\u2013529","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2388_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ijrobp.2023.04.010","volume":"117","author":"DE Spratt","year":"2023","unstructured":"Spratt\u00a0DE, Liu\u00a0VYT, Michalski\u00a0J, Davicioni\u00a0E, Berlin\u00a0A, Simko\u00a0JP et\u00a0al (2023) Genomic classifier performance in intermediate-risk prostate cancer: results from NRG oncology\/RTOG 0126 randomized phase\u00a03 trial. Int J Radiat Oncol Biol Phys 117(2):370\u2013377","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2388_CR11","doi-asserted-by":"publisher","first-page":"e2300214","DOI":"10.1200\/PO.23.00214","volume":"7","author":"RL Bitting","year":"2023","unstructured":"Bitting\u00a0RL, Wu\u00a0Y, Somarelli\u00a0JA, Proudfoot\u00a0JA, Liu\u00a0Y, Davicioni\u00a0E et\u00a0al (2023) Transcriptomic signatures associated with outcomes in recurrent prostate cancer treated with salvage radiation, androgen-deprivation therapy, and enzalutamide: correlative analysis of the STREAM trial. JCO Precis Oncol 7:e2300214","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"2388_CR12","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ijrobp.2022.12.006","volume":"115","author":"P Sutera","year":"2023","unstructured":"Sutera\u00a0P, Deek\u00a0MP, Van der Eecken\u00a0K, Shetty\u00a0AC, Chang\u00a0JH, Hodges\u00a0T et\u00a0al (2023) WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer. Int J Radiat Oncol Biol Phys 115(5):1095\u20131101","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2388_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.annonc.2023.04.515","volume":"34","author":"PA Sutera","year":"2023","unstructured":"Sutera\u00a0PA, Shetty\u00a0AC, Hakansson\u00a0A, Van der Eecken\u00a0K, Song\u00a0Y, Liu\u00a0Y et\u00a0al (2023) Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. Ann Oncol 34(7):605\u2013614","journal-title":"Ann Oncol"},{"issue":"8","key":"2388_CR14","doi-asserted-by":"publisher","first-page":"EVIDoa2300023","DOI":"10.1056\/EVIDoa2300023","volume":"2","author":"DE Spratt","year":"2023","unstructured":"Spratt\u00a0DE, Tang\u00a0S, Sun\u00a0Y, Huang\u00a0HC, Chen\u00a0E, Mohamad\u00a0O et\u00a0al (2023) Artificial intelligence predictive model for hormone therapy use in prostate cancer. NEJM Evid 2(8):EVIDoa2300023","journal-title":"NEJM Evid"},{"key":"2388_CR15","doi-asserted-by":"publisher","unstructured":"Ross\u00a0AE, Zhang\u00a0J, Huang\u00a0HC, Yamashita\u00a0R, Keim-Malpass\u00a0J, Simko\u00a0JP et\u00a0al. (2024) External validation of a digital pathology-based multimodal artificial intelligence architecture in the NRG\/RTOG 9902 phase 3 trial. Eur Urol Oncol 7(5):1024\u20131033. https:\/\/doi.org\/10.1016\/j.euo.2024.01.004","DOI":"10.1016\/j.euo.2024.01.004"},{"key":"2388_CR16","doi-asserted-by":"publisher","unstructured":"Repka MC, Sholklapper T, Zwart AL, Danner M, Ayoob M, Yung T et al (2024) Prognostic utility of biopsy-based PTEN and ERG status on biochemical progression and overall survival after SBRT for localized prostate cancer. Front Oncol 14:1381134. https:\/\/doi.org\/10.3389\/fonc.2024.1381134","DOI":"10.3389\/fonc.2024.1381134"},{"issue":"1","key":"2388_CR17","doi-asserted-by":"publisher","first-page":"5.e1","DOI":"10.1016\/j.urolonc.2021.08.013","volume":"40","author":"M Ramotar","year":"2022","unstructured":"Ramotar\u00a0M, Chua\u00a0MLK, Truong\u00a0H, Hosni\u00a0A, Pintilie\u00a0M, Davicioni\u00a0E et\u00a0al (2022) Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. Urol Oncol 40(1):5.e1\u20135.e13","journal-title":"Urol Oncol"},{"issue":"17","key":"2388_CR18","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy\u00a0FC, Donovan\u00a0JL, Lane\u00a0JA, Metcalfe\u00a0C, Davis\u00a0M, Turner\u00a0EL et\u00a0al (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N\u00a0Engl J Med 388(17):1547\u20131558","journal-title":"N Engl J Med"},{"issue":"20","key":"2388_CR19","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","volume":"41","author":"M Hussain","year":"2023","unstructured":"Hussain\u00a0M, Tombal\u00a0B, Saad\u00a0F, Fizazi\u00a0K, Sternberg\u00a0CN, Crawford\u00a0ED et\u00a0al (2023) Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase\u00a0III ARASENS trial. J\u00a0Clin Oncol 41(20):3595\u20133607","journal-title":"J Clin Oncol"},{"issue":"1","key":"2388_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi\u00a0KN, Agarwal\u00a0N, Bjartell\u00a0A, Chung\u00a0BH, Pereira de Santana Gomes\u00a0AJ, Given\u00a0R et\u00a0al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N\u00a0Engl J Med 381(1):13\u201324","journal-title":"N Engl J Med"},{"issue":"2","key":"2388_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis\u00a0ID, Martin\u00a0AJ, Stockler\u00a0MR, Begbie\u00a0S, Chi\u00a0KN, Chowdhury\u00a0S et\u00a0al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N\u00a0Engl J Med 381(2):121\u2013131","journal-title":"N Engl J Med"},{"issue":"4","key":"2388_CR22","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi\u00a0K, Tran\u00a0N, Fein\u00a0L, Matsubara\u00a0N, Rodriguez-Antolin\u00a0A, Alekseev\u00a0BY et\u00a0al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N\u00a0Engl J Med 377(4):352\u2013360","journal-title":"N Engl J Med"},{"issue":"7","key":"2388_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","volume":"32","author":"S Halabi","year":"2014","unstructured":"Halabi\u00a0S, Lin\u00a0C\u2011Y, Kelly\u00a0WK, Fizazi\u00a0KS, Moul\u00a0JW, Kaplan\u00a0EB et\u00a0al (2014) Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. JCO 32(7):671\u2013677","journal-title":"JCO"},{"issue":"4","key":"2388_CR24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41391-020-0226-2","volume":"23","author":"JJ Tosoian","year":"2020","unstructured":"Tosoian\u00a0JJ, Birer\u00a0SR, Karnes\u00a0JR, Zhang\u00a0J, Davicioni\u00a0E, Klein\u00a0EE et\u00a0al (2020) Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a\u00a022-gene genomic classifier. Prostate Cancer Prostatic Dis 23(4):646\u2013653","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"2388_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijrobp.2018.08.030","volume":"103","author":"A Berlin","year":"2019","unstructured":"Berlin\u00a0A, Murgic\u00a0J, Hosni\u00a0A, Pintilie\u00a0M, Salcedo\u00a0A, Fraser\u00a0M et\u00a0al (2019) Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image guided radiation therapy without hormone therapy. Int J Radiat Oncol 103(1):84\u201391","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"2388_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/pcan.2016.58","volume":"20","author":"PL Nguyen","year":"2017","unstructured":"Nguyen\u00a0PL, Martin\u00a0NE, Choeurng\u00a0V, Palmer-Aronsten\u00a0B, Kolisnik\u00a0T, Beard\u00a0CJ et\u00a0al (2017) Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis 20(2):186\u2013192","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"2388_CR27","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ijrobp.2013.04.043","volume":"86","author":"SJ Freedland","year":"2013","unstructured":"Freedland\u00a0SJ, Gerber\u00a0L, Reid\u00a0J, Welbourn\u00a0W, Tikishvili\u00a0E, Park\u00a0J et\u00a0al (2013) Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 86(5):848\u2013853","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2388_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijrobp.2021.09.034","volume":"113","author":"J Tward","year":"2022","unstructured":"Tward\u00a0J, Lenz\u00a0L, Flake\u00a0DD, Rajamani\u00a0S, Yonover\u00a0P, Olsson\u00a0C et\u00a0al (2022) The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. Int J Radiat Oncol 113(1):66\u201376","journal-title":"Int J Radiat Oncol"},{"issue":"30","key":"2388_CR29","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","volume":"34","author":"RD Tendulkar","year":"2016","unstructured":"Tendulkar\u00a0RD, Agrawal\u00a0S, Gao\u00a0T, Efstathiou\u00a0JA, Pisansky\u00a0TM, Michalski\u00a0JM et\u00a0al (2016) Contemporary update of a\u00a0multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J\u00a0Clin Oncol 34(30):3648\u20133654","journal-title":"J Clin Oncol"},{"issue":"4","key":"2388_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","volume":"7","author":"FY Feng","year":"2021","unstructured":"Feng\u00a0FY, Huang\u00a0H\u2011C, Spratt\u00a0DE, Zhao\u00a0S, Sandler\u00a0HM, Simko\u00a0JP et\u00a0al (2021) Validation of a\u00a022-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG\/RTOG 9601 randomized clinical trial. JAMA Oncol 7(4):544\u2013552","journal-title":"JAMA Oncol"},{"key":"2388_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3233\/CBM-160620","volume":"17","author":"MO Koch","year":"2016","unstructured":"Koch\u00a0MO, Cho\u00a0JS, Kaimakliotis\u00a0HZ, Cheng\u00a0L, Sangale\u00a0Z, Brawer\u00a0M et\u00a0al (2016) Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. Cancer Biomark 17(1):83\u201388. https:\/\/doi.org\/10.3233\/CBM-160620","journal-title":"Cancer Biomarkers"},{"issue":"6","key":"2388_CR32","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.euo.2020.01.005","volume":"4","author":"RL Bitting","year":"2021","unstructured":"Bitting\u00a0RL, Healy\u00a0P, George\u00a0DJ, Anand\u00a0M, Kim\u00a0S, Mayer\u00a0T et\u00a0al (2021) Phase\u00a0II trial of Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk prostate-specific antigen recurrent prostate cancer: the STREAM trial. Eur Urol Oncol 4(6):948\u2013954","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"2388_CR33","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1200\/JCO.22.01662","volume":"41","author":"PT Tran","year":"2023","unstructured":"Tran\u00a0PT, Lowe\u00a0K, Tsai\u00a0H\u2011L, Song\u00a0DY, Hung\u00a0AY, Hearn\u00a0JWD et\u00a0al (2023) Phase\u00a0II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial. JCO 41(6):1307\u20131317","journal-title":"JCO"},{"issue":"5","key":"2388_CR34","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost\u00a0P, Reynders\u00a0D, Decaestecker\u00a0K, Fonteyne\u00a0V, Lumen\u00a0N, Bruycker\u00a0AD et\u00a0al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a\u00a0prospective, randomized, multicenter phase\u00a0II trial. JCO 36(5):446\u2013453","journal-title":"JCO"},{"issue":"5","key":"2388_CR35","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips\u00a0R, Shi\u00a0WY, Deek\u00a0M, Radwan\u00a0N, Lim\u00a0SJ, Antonarakis\u00a0ES et\u00a0al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase\u00a02 randomized clinical trial. JAMA Oncol 6(5):650\u2013659","journal-title":"JAMA Oncol"},{"issue":"6","key":"2388_CR36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","volume":"9","author":"C Tang","year":"2023","unstructured":"Tang\u00a0C, Sherry\u00a0AD, Haymaker\u00a0C, Bathala\u00a0T, Liu\u00a0S, Fellman\u00a0B et\u00a0al (2023) Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase\u00a02 randomized clinical trial. JAMA Oncol 9(6):825\u2013834","journal-title":"JAMA Oncol"},{"issue":"17\u201318","key":"2388_CR37","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1101\/gad.315739.118","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang\u00a0G, Zhao\u00a0D, Spring\u00a0DJ, DePinho\u00a0RA (2018) Genetics and biology of prostate cancer. Genes Dev 32(17\u201318):1105\u20131140","journal-title":"Genes Dev"},{"issue":"29","key":"2388_CR38","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek\u00a0MP, Eecken KVd, Sutera\u00a0P, Deek\u00a0RA, Fonteyne\u00a0V, Mendes\u00a0AA et\u00a0al (2022) Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in Oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. JCO 40(29):3377\u20133382","journal-title":"JCO"},{"key":"2388_CR39","doi-asserted-by":"publisher","unstructured":"Bartlett\u00a0JM, Bayani\u00a0J, Marshall\u00a0A, Dunn\u00a0JA, Campbell\u00a0A, Cunningham\u00a0C et\u00a0al. (2016) Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. J Natl Cancer Inst 108(9):djw050. https:\/\/doi.org\/10.1093\/jnci\/djw050","DOI":"10.1093\/jnci\/djw050"},{"issue":"3","key":"2388_CR40","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/annonc\/mds334","volume":"24","author":"P Dubsky","year":"2013","unstructured":"Dubsky\u00a0P, Filipits\u00a0M, Jakesz\u00a0R, Rudas\u00a0M, Singer\u00a0CF, Greil\u00a0R et\u00a0al (2013) Endopredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 24(3):640\u2013647","journal-title":"Ann Oncol"},{"issue":"5","key":"2388_CR41","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-13-1845","volume":"20","author":"M Filipits","year":"2014","unstructured":"Filipits\u00a0M, Nielsen\u00a0TO, Rudas\u00a0M, Greil\u00a0R, St\u00f6ger\u00a0H, Jakesz\u00a0R et\u00a0al (2014) The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 20(5):1298\u20131305","journal-title":"Clin Cancer Res"},{"key":"2388_CR42","unstructured":"(2024) EAU Guidelines Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3. EAU Guidelines Office, Arnhem, The Netherlands. https:\/\/uroweb.org\/guidelines"},{"issue":"3","key":"2388_CR43","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1016\/j.clgc.2016.08.012","volume":"15","author":"JM Lobo","year":"2017","unstructured":"Lobo\u00a0JM, Trifiletti\u00a0DM, Sturz\u00a0VN, Dicker\u00a0AP, Buerki\u00a0C, Davicioni\u00a0E et\u00a0al (2017) Cost-effectiveness of the decipher genomic classifier to guide individualized decisions for early radiation therapy after prostatectomy for prostate cancer. Clin Genitourin Cancer 15(3):e299\u2013e309","journal-title":"Clin Genitourin Cancer"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-025-02388-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:11:56Z","timestamp":1757146316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-025-02388-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1007\/s00066-025-02388-x","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K.B.\u00a0Spohn, D.\u00a0M.\u00a0Aebersold, C.\u00a0Albrecht, D.\u00a0Boehmer, U.\u00a0Ganswindt, N.-S.\u00a0Schmidt-Hegemann, S.\u00a0Hoecht, T.\u00a0H\u00f6lscher, S.\u00a0A.\u00a0Koerber, A.-C.\u00a0Mueller, P.\u00a0Niehoff, J.C.\u00a0Peeken, M.\u00a0Pinkawa, B.\u00a0Polat, M.\u00a0Shelan, F.\u00a0Wolf, C.\u00a0Zamboglou, D.\u00a0Zips, and T.\u00a0Wiegel declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}